In vitro cytotoxic potential of Yacon (Smallanthus sonchifolius) against HT-29, MCF-7 and HDFn cell lines | Zendy

P. Mendoza Rachelle | Zendy; S. Vidar Warren | Zendy; G. Oyong Glenn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro cytotoxic potential of Yacon (Smallanthus sonchifolius) against HT-29, MCF-7 and HDFn cell lines

Author(s) -

P. Mendoza Rachelle,

S. Vidar Warren,

G. Oyong Glenn

Publication year - 2017

Publication title -

journal of medicinal plants research

Language(s) - English

Resource type - Journals

ISSN - 1996-0875

DOI - 10.5897/jmpr2016.6205

Subject(s) - yacón , cytotoxicity , mcf 7 , cytotoxic t cell , chemistry , colorectal cancer , viability assay , in vitro , cell culture , cancer , cancer cell , pharmacology , cancer research , biology , biochemistry , medicine , human breast , genetics

Yacon (Smallanthus sonchifolius) tubers and leaves have been used widely as foodstuff and as remedy for urinary ailments, muscle pain, hyperlipidemia and diabetes mellitus. Recent studies have investigated on isolating active components for their anti-cancer potential against melanoma, cervical cancer and colon cancer. In this study, the cytotoxicity potential of hexane, methanol and DCM extracts of yacon leaves was assessed against MCF-7 (breast cancer), HT-29 (colon cancer) and HDFn (normal human dermal fibroblast) cell lines by using AlamarBlue® assay. Results showed significant reduction in cellular viability of MCF-7 cell lines caused by hexane, methanol and DCM extracts in a dose dependent manner, with DCM being the most potent. The DCM extract also produced significant cytotoxic activity against HT-29 cells, with IC50 lower than 5-fluorouracil. Effect on HDFn showed that three yacon extracts produced significantly lower cytotoxicity compared to drug controls with the DCM extract showing the least toxicity. Key words: Yacon, alamar, breast, colon, cancer, MCF-7, HT-29..

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research